Background: Ulcerative colitis (UC) is a recurrent inflammatory bowel disease (IBD) that causes long-lasting inflammation on the innermost lining of the colon and rectum. Leaf decoctions of have been used in traditional medicine either alone or in combination with other plant preparations to treat the disease.
Aim: In this study, we investigated the effect of hydroethanolic extract of have been used in traditional medicine either alone or in combination with other plant preparations to treat the disease.
Method: Male Sprague Dawley rats received oral treatment of either saline (10 ml/kg), sulfasalazine (500 mg/kg), or CVE (30-300 mg/kg) daily for 7 days. On day 4, colitis was induced by a single intrarectal administration of 500 l of acetic acid (4% //.
Results: CVE significantly ( < 0.05) prevented colonic ulceration and reduced the inflammatory score. Serum levels of TNF- and IL-6 were significantly reduced. Depletion of superoxide dismutase (SOD) and catalase (CAT) activities by acetic acid was significantly inhibited while lipid peroxidation indexed as malondialdehyde (MDA) level in the colon was reduced. However, loss of body weight was not significantly affected by treatment with CVE.
Conclusion: This data suggest that CVE has a potential antiulcerative effect.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026722 | PMC |
http://dx.doi.org/10.1155/2020/8785497 | DOI Listing |
Orv Hetil
January 2025
1 Semmelweis Egyetem, Általános Orvostudományi Kar, Belgyógyászati és Onkológiai Klinika Budapest, Korányi S. u. 2/a, 1083 Magyarország.
BMC Gastroenterol
January 2025
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Background: Previous studies have suggested an association between inflammatory bowel disease (IBD), and pancreatitis, including acute pancreatitis (AP) and chronic pancreatitis (CP). We aimed to examine the potential causal relationship between IBD and pancreatitis using the Mendelian randomization (MR) method.
Methods: We obtained data from genome-wide association studies (GWASs) in European individuals for IBD and its main subtypes, Crohn's disease (CD) and ulcerative colitis (UC) (31,665 IBD cases, 13,768 UC cases, 17,897 CD cases and 33,977 controls).
Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Background: Mesalamine is the first-line drug for treating mild-to-moderate ulcerative colitis (UC); however, some patients develop symptoms of intolerance. Although several desensitization methods have been reported, these desensitization regimens were rather complicated for physicians to prescribe in daily clinical practice; therefore, it has not yet become a major therapeutic option for intolerance patients. Thus, we developed an alternative desensitization protocol.
View Article and Find Full Text PDFJ Gastroenterol Hepatol
January 2025
Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China.
Intern Med J
January 2025
Crohn's Colitis Cure, Sydney, New South Wales, Australia.
Background: The burden of inflammatory bowel disease (IBD) is often reported on from a system or cost viewpoint. We created and explored a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort.
Aim: To create and explore a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort, and correlate PPBoD scores with demographics, disease and treatment factors.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!